Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase II Trial
100%
Biomarker Analysis
100%
Metastatic Colorectal Cancer (mCRC)
100%
Treatment Refractory
100%
Azacitidine
100%
Pembrolizumab
100%
Correlative Biomarkers
100%
Online Treatment
57%
CD8+
42%
Tumor
28%
Overall Response Rate
28%
Tumor DNA
28%
DNA Demethylation
28%
Immune Modulation
28%
DNA Methylation (DNAm)
14%
Median Overall Survival
14%
Stable Disease
14%
Progression-free Survival
14%
Antitumor Activity
14%
Partial Response
14%
As(III)
14%
Tolerability
14%
Clinical Trials
14%
Tumor Tissue
14%
Clinical Efficacy
14%
Combination Regimen
14%
Demethylation
14%
Overall Survival
14%
Trial Registration
14%
Cytotoxic Effect
14%
Accruals
14%
Refractory Patients
14%
Antitumor Immune Response
14%
DNA Methyltransferase Inhibitor
14%
Clinical Activity
14%
Background DNA
14%
Immunomodulation
14%
3-cycle
14%
Immunomodulatory Effect
14%
Upregulated Genes
14%
Endogenous Retroviral Element
14%
Concurrent Treatment
14%
Cancer-testis Antigen
14%
DNA Mismatch Repair Proficient
14%
Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
14%
Immune Gene Sets
14%
Well Tolerated
14%
Median Progression-free Survival
14%
Treatment-related Adverse Events
14%
Fixed Dose
14%
Gene Promoter Region
14%
Tumor Immune
14%
Paired Biopsy
14%
Pembrolizumab Monotherapy
14%
Single-arm Trial
14%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Metastatic Colorectal Cancer
100%
Chemotherapy Regimens
100%
Azacitidine
100%
Pembrolizumab
100%
Neoplasm
85%
CD8 Antigen
42%
Progression Free Survival
28%
Overall Survival
28%
Adverse Event
14%
Clinical Trial
14%
Antitumor Activity
14%
Tolerability
14%
Monotherapy
14%
DNA Methyltransferase Inhibitor
14%
Immunomodulation
14%
Cancer Testis Antigen
14%
Cytotoxicity
14%
Diseases
14%
Immunology and Microbiology
Arm
100%
Pembrolizumab
100%
Colorectal Carcinoma
100%
CD8
50%
Immunomodulation
50%
Progression Free Survival
33%
Overall Survival
33%
DNA Demethylation
33%
Pretreatment
33%
DNA Methylation
16%
Immune Response
16%
Promoter Region
16%
Antineoplastic Activity
16%
Cytotoxicity
16%
Mismatch DNA Repair
16%
Demethylation
16%
Cancer Testis Antigen
16%
Gene Promoter
16%
Neuroscience
Azacitidine
100%
Lambrolizumab
100%
Chemotherapy
100%
Biological Marker
100%
Colorectal Carcinoma
100%
CD8
42%
Promoter Region
28%
DNA Demethylation
28%
Cytotoxicity
14%
DNA Methylation
14%
DNA Mismatch Repair
14%
DNA Methyltransferase
14%
Cancer Testis Antigen
14%
Biochemistry, Genetics and Molecular Biology
Azacitidine
100%
Pembrolizumab
100%
CD8
42%
Immunomodulation
42%
Overall Survival
28%
DNA Demethylation
28%
Progression Free Survival
28%
DNA Methylation
14%
Promoter Region
14%
Cytotoxicity
14%
DNA Mismatch Repair
14%
Clinical Trial
14%
Demethylation
14%
DNA Methyltransferase
14%
Immune Response
14%
Antineoplastic Activity
14%
Pribnow Box
14%